Thomas R. Staab II - 11 Sep 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Reporting relationship: Chief Financial Officer
Issuer ticker: TENX
Reported as of: 11 Sep 2026
Net transaction value: +$10,981
SEC form: 4
Accepted by SEC: 15 Sep 2026, 21:30:04 UTC
Prior SEC filing: 13 May 2026
Source filing: View source filing
Reporting owner signature: /s/ S. Halle Vakani, as Attorney-in-Fact

Key filing fact

Thomas R. Staab II filed Form 4 for TENAX THERAPEUTICS, INC. (TENX) on 15 Sep 2026.

Key facts

This page summarizes Thomas R. Staab II's Form 4 filing for TENAX THERAPEUTICS, INC. (TENX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Sep 2026, 21:30.

Change

Previous filing in this sequence was filed on 13 May 2026.
Current net transaction value: +$10,981.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001230708 Primary reporting owner

STAAB THOMAS R II

Relationship: Chief Financial Officer
Address: 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL
Signature: /s/ S. Halle Vakani, as Attorney-in-Fact
Signature date: 15 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TENX transaction

Common Stock

Purchase

Transaction value: $10,981
Shares: +5,675
Change %: +57%
Price: $1.94
Shares after: 15,675
Date: 11 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 450,000
Date: 11 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 450,000
Exercise price: $11.95
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Footnote F2

The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.